Eveready Industries India Ltd. — Q2 and H1 FY27 — 2 November 2026

1. Overall Tone of Management

Cautious. Management emphasized eight consecutive quarters of revenue growth and strength in premium categories, but acknowledged that the operating backdrop has worsened: zinc prices were up 36% year on year, input inflation and currency volatility remain headwinds, and management said “H2 will be more difficult than H1.” Margin recovery is expected to be incomplete in Q3 and largely completed only in Q4. Confidence in execution is evident, but not in an easy near-term environment.

2. Key Themes from Management Commentary

Growth remains positive, but cost pressure is catching up: Q2 revenue rose 10.7% to ₹428.2 crore; EBITDA grew 8.9% to ₹58.8 crore, with a 12.6% margin. Management attributed a 20-basis-point margin contraction to elevated material costs and channel/product mix.
Battery premiumization is a key growth driver: Alkaline volumes grew 30% year on year, and Eveready said it gained share in the segment. Carbon-zinc remained stable, though management described the overall dry-cell market as mature, with sluggish volumes but value growth from premiumization.
Jammu localization is moving from setup to execution: Commercial production began in May and billing in September. Local production is expected to improve alkaline margins, but the benefit will build over time as volumes, utilization and vendor localization increase.
Adjacencies are being scaled, not yet quantified broadly: Newer areas include portable liquid vaporizers, mosquito racquets, rechargeable flashlights, emergency lighting and electrical accessories. Management said half of H1 growth came from products launched within the last 24 months, excluding alkaline.
Balance-sheet repair continues: Net debt was ₹153 crore at September-end, before most of the additional ₹80–90 crore received from the second Noida plot sale in October. Management said most of those proceeds were used to reduce debt.
Unresolved regulatory and subsidy issues: EPR requirements for dry-cell batteries remain ambiguous, while Jammu’s incentive registration is pending because funding has not been released.

3. Q&A Analysis

Margins, input costs and pricing

Analysts asked: What caused margin pressure, and when could margins recover given zinc-price movements and recent price increases?
Management responded: The quarter’s 20-basis-point operating-margin contraction reflected elevated material costs and mix. Price corrections have been taken, but recovery may not be complete in Q3; remaining pressure should be covered in Q4.
Assessment: The response was relatively direct, but it tempers the opening message of “profitable growth.” Management clarified that easing zinc alone does not guarantee immediate margin relief because other costs and timing also matter.
Quote: “We may not fully recover this in Q3… if anything remains, it will definitely be fully covered in Q4.”

Jammu plant: ramp-up, margins and subsidy

Analysts asked: When will Jammu contribute to revenue, how much alkaline supply is now local, and what margin improvement is expected?
Management responded: Commercial production started in May; billing began in September after product ageing and depletion of imported stock. About 10% of Q2 alkaline sales came from the plant, mostly in the final month; Q3 supply is expected to be largely Jammu-produced. Local production is currently estimated to be at least 6–7% better than imports, with further gains dependent on utilization and localization.
Assessment: The operational explanation was specific. The margin benefit remains qualitative at the consolidated level because alkaline’s share of total dry-cell sales is still below management’s desired level.
Subsidy: Registration has not been granted, and no accrual can be assumed. If fully approved, management estimated ₹20–25 crore annually for up to 10 years, subject to the scheme cap.

Debt reduction and Noida asset sale

Analysts asked: How quickly can net debt fall, and how much of the land-sale proceeds have been received and applied?
Management responded: The September net-debt figure of ₹153 crore excludes ₹80–90 crore received in October for the second plot; most of that cash was used to reduce debt. With no major capex planned, management said debt-free status within two years was reasonable and could arrive sooner.
Assessment: This was among management’s strongest answers, although the debt-free timeline remains conditional on no major new capex.

New products and growth potential

Analysts asked: Can new-product revenues be quantified, and could the mosquito business reach ₹100 crore by FY29?
Management responded: Half of H1 growth came from newer products, defined as launches in the past 24 months, excluding alkaline. Management said the combined mosquito business—racquets and liquid vaporizers—could exceed ₹100 crore by FY29. For the roughly ₹2,800-crore liquid-vaporizer market, it called a 3–4% share realistic.
Assessment: This is a concrete target, but management deferred a fuller category plan to a future quarter. It was appropriately more restrained than the analyst’s proposed 5–6% market-share assumption.

Market share, competition and category demand

Analysts asked: Are battery share gains coming from competitors affected by supply issues, and why is the dry-cell market’s volume growth weak?
Management responded: Current gains are mainly in alkaline; it is too early to attribute share gains to Panasonic-related supply disruptions, with Nielsen data lagging. Management characterized the dry-cell market as mature, with value growth from alkaline replacing some zinc usage but overall volumes sluggish.
Assessment: Management avoided attributing gains prematurely and gave a plausible structural explanation. The answer highlights that value growth is more dependable than category volume growth.

EPR and regulatory uncertainty

Analysts asked: Is the company compliant with dry-cell EPR rules, what is the financial impact, and when will clarity arrive?
Management responded: Pricing and compliance requirements remain ambiguous; discussions with regulators are active, and management expects the issue to be resolved in the quarter.
Assessment: The answer was partial: no quantified exposure or clear description of current provisioning was provided. The expected resolution is a near-term commitment to track.

Lighting profitability and channel mix

Analysts asked: What is the split between consumer and professional lighting, and has the division reached breakeven?
Management responded: About 85% of lighting is B2C. H1 lighting was close to breakeven on a fully allocated basis; B2C was EBITDA-positive, while professional lighting incurred losses as management assesses operating models.
Assessment: A useful, candid disclosure. Professional lighting is a clear execution risk despite strength in emergency bulbs and other consumer categories.

Other points

A&P spending was not materially cut to protect margins; management said it remains around 10–10.5% of revenue.
B2B batteries account for roughly 10% of company revenue; management could not quantify alkaline’s B2B mix.
White-label alkaline opportunities are being explored, but certifications and customer qualification could take 1–2 years.
No acquisition is actively being pursued; management said there is no major capex on the cards.

4. Guidance / Outlook

Quantitative guidance

Q2 FY27 results: Revenue ₹428.2 crore, up 10.7%; EBITDA ₹58.8 crore, up 8.9%; EBITDA margin 12.6%.
Margin recovery: Q3 may not fully recover cost pressure; any remaining impact is expected to be covered in Q4.
Debt: Debt-free within two years is a reasonable expectation if no major capex is undertaken; management suggested it could happen earlier following the October property proceeds.
New categories: Combined mosquito racquets and liquid vaporizers could exceed ₹100 crore by FY29. Management considers 3–4% share in the liquid-vaporizer market realistic.
A&P: Expected to remain around 10–10.5% of revenue.
Jammu incentive: Potentially ₹20–25 crore per year for up to 10 years if approved in full; not yet approved or accrued.
White-label alkaline: A 1–2-year qualification and compliance journey.

Qualitative signals

Management expects H2 to be more difficult than H1 because commodity prices are hardening; it will use pricing, efficiency and cost management to pursue consistent results.
Jammu should supply most alkaline sales from Q3 onward. Margin benefits are expected to develop progressively with utilization and localization.
Management plans to provide a more detailed multi-year category and growth plan around March; it did not provide a current revenue CAGR or margin target.
No major capex is currently planned, subject to future decisions.

5. Standout Statements

“H2 will be more difficult than H1.” A notably candid qualification of the upbeat growth narrative.
“We may not fully recover this in Q3… if anything remains, it will definitely be fully covered in Q4.” Makes the margin-recovery timetable explicit.
“The dry cell market by value continues to grow. It is the volumes that are somewhat sluggish.” A useful distinction between premiumization and underlying unit demand.
“Half our growth came from our core categories and half our growth came from new products…” Suggests adjacency launches are already material to growth, though management did not disclose their absolute contribution.
“In the long run… local production… should have some improvement in margins,” but vendor localization and higher alkaline salience are still needed for a meaningful consolidated impact.
“The professional lighting… is at a transition point.” A frank admission that this business is not yet delivering satisfactory economics.

6. Red Flags / Positive Signals

Red flags
– Zinc and other input-cost inflation is pressuring margins despite pricing actions; the company expects full recovery only by Q4.
– EPR rules remain unresolved, with no quantified impact disclosed.
– Jammu’s incentive remains unapproved; prior calls also described the registration and funding as pending.
– Professional lighting generated H1 losses; overall lighting was only near breakeven.
– Management has repeatedly deferred a multi-year growth/CAGR framework, now indicating March.
– Alkaline growth appears to be moderating from the 60–70%+ rates discussed in FY26, although the current quarter’s 30% growth remains strong.

Positive signals
– Eight consecutive quarters of year-on-year revenue growth.
– Alkaline volumes grew 30%, with reported share gains.
– Jammu is producing and billing; local manufacturing is expected to improve unit economics.
– Noida sale proceeds have largely been directed to debt reduction, with no major capex planned.
– Rechargeable flashlights and emergency LED bulbs grew 32.2% and 26%, respectively.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

Q2 FY26 — 6 November 2025

Dominant tone: Neutral
Major themes this quarter:
Resilient rural demand and a largely stable cost environment at the time.
Alkaline share gains and strong growth; carbon-zinc leadership.
Flashlight rechargeables growing while battery-operated products softened.
Jammu construction on schedule; manufacturing realignment and Noida monetization under consideration.
Tone shift vs previous quarter: N/A (baseline)
What changed: Baseline among the supplied calls. Management was positive on demand and the Jammu plan, but stressed commodity risks, margin discipline and uncertainty over asset realignment.

Q3 FY26 — 6 February 2026

Dominant tone: Optimistic
Major themes this quarter:
Fifth consecutive quarter of revenue growth; batteries as the principal driver.
Alkaline growth of about 72% and continued share gains.
Jammu facility progressing toward completion, with a claimed margin benefit of nearly 10% for the segment.
Noida divestment and manufacturing realignment as balance-sheet priorities.
Tone shift vs previous quarter: More Optimistic
What changed:
Confidence strengthened as revenue and EBITDA grew 10.1% and 13%, respectively.
Management introduced a more specific expectation that Jammu could improve alkaline margins by nearly 10%.
BIS implementation was framed as a potential tailwind for organized flashlight players.

Q4 FY26 — 30 April 2026

Dominant tone: Optimistic
Major themes this quarter:
FY26 revenue growth of 8.2%, EBITDA growth of 8.9%, and 11.5% full-year EBITDA margin.
Jammu commissioning and a transition from imported to domestic alkaline batteries.
Debt reduction, Noida land monetization and premiumization.
FY27 positioned as a year of plant ramp-up and continued expansion in adjacencies.
Tone shift vs previous quarter: No Change
What changed:
Management moved from construction updates to commissioning, expecting more than 100 million units in Jammu’s first year.
It said FY27 margins should hold around FY26’s 11.5% despite stronger headwinds.
The facility’s payback was described as 5–6 years, while operational breakeven was expected from year one.

Q2 FY27 — 2 November 2026

Dominant tone: Neutral (with more cautious near-term commentary)
Major themes this quarter:
Persistent commodity, currency and geopolitical pressure; zinc averaged 36% higher year on year.
Continued revenue growth, but margin contraction and delayed full recovery.
Jammu production and billing have begun; greater localization expected in Q3.
New products and adjacencies, alongside debt reduction and unresolved EPR/subsidy matters.
Tone shift vs previous quarter: More Cautious
What changed:
The FY27 outlook shifted from holding margins around FY26 levels to a more explicit warning that H2 will be harder than H1.
Jammu is now operational, but Q2 alkaline sales were still mostly from imported stock; the margin uplift remains prospective.
Growth outlook remains positive, but management again deferred a multi-year CAGR plan, now to around March.

Trajectory Summary: Management’s confidence rose as FY26 growth strengthened and Jammu approached commissioning. The current call marks a more cautious phase: the plant is operating, but raw-material inflation is intensifying, margin recovery is delayed, and management is less willing to imply an easy H2.

b. Tracking Past Commitments vs Outcomes

Q2/Q3 FY26: Jammu to be completed by FY26-end and commence production shortly thereafter.
Expected: Commissioning and a gradual shift from imports to local alkaline production.
Outcome: Commercial production began in May 2026; billing began in September. Q2 supply was still mostly imported, with about 10% from Jammu in the final month; Q3 is expected to be mostly local. ✅ Delivered, with ramp-up still underway.
Q3 FY26: Initial Jammu utilization of 25–30%, rising to 40–50% over time; margin improvement of nearly 10%.
Expected: Early utilization and a meaningful alkaline margin uplift.
Outcome: Current call describes the plant as running near desired capacity, but provides no utilization percentage or realized margin uplift. Local production is estimated to be 6–7% better than imports under current conditions; further gains depend on localization. ⏳ Partly evidenced; full benefit not yet demonstrated.
Q4 FY26: Maintain FY26-like EBITDA margins of around 11.5% in FY27.
Expected: Hold full-year margin around the prior-year level despite headwinds.
Outcome: Q2 margin is 12.6%, but down 20 basis points year on year; management warns H2 will be harder and offers no full-year margin guidance. ⏳ Not yet verifiable; confidence has softened.
Q3 FY26: Noida monetization targeted within six months; proceeds to reduce debt.
Expected: Complete sale and strengthen the balance sheet.
Outcome: The second plot transaction closed on 13 October, and ₹80–90 crore was received; most was used to reduce debt. ✅ Delivered.
Q4 FY26: Continue debt reduction in FY27, with no major capex beyond routine spending.
Expected: Debt to fall further, supported by property proceeds and cash generation.
Outcome: Net debt was ₹153 crore at September-end before the October proceeds; management expects debt-free status within two years and potentially sooner. ✅ Progressing; final timeline remains conditional.
Q2/Q3 FY26: Jammu incentive registration expected to support economics.
Expected: Government incentive approval and eventual benefit.
Outcome: Registration remains pending; funds have not been released. No accrual is permitted. ⏳ Delayed.
Q3 FY26: BIS flashlight rules to support branded-player growth from FY27.
Expected: Organized players to benefit as smaller competitors incur compliance costs.
Outcome: Current call does not identify a quantified BIS-driven gain or market-share impact. ❌ Not yet evidenced in the current call.

c. Narrative Shifts

From “Jammu commissioning” to “Jammu economics”: Discussion has moved to billing, localization and margin contribution, though the scale of benefit is still to be proven.
From a largely domestic premiumization story to broader adjacency targets: Mosquito products now have an explicit FY29 revenue ambition; liquid vaporizers and electrical accessories are gaining attention.
Near-term cost risks have intensified: Earlier calls discussed zinc and currency volatility; the current call adds a 36% year-on-year zinc increase, hardening commodities and a more difficult H2.
Professional lighting has become a clearer profitability concern: Current management explicitly reports losses in that business and says it is assessing operating models.
Unresolved issues persist: Jammu incentives have remained pending across calls, while EPR ambiguity is a newer regulatory uncertainty.
The multi-year growth target remains absent: Management previously deferred a three-year CAGR outlook and has now pushed a more comprehensive plan to around March.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management has followed through on major operational milestones: Jammu began production and billing, Noida monetization closed, and debt reduction has continued. It has also been reasonably candid about professional-lighting losses and the harder H2 outlook.

Credibility is tempered by repeated deferrals of quantified medium-term guidance, an incentive approval that has remained pending for multiple calls, and the gap between earlier strong expectations for Jammu’s margin contribution and the limited realized evidence so far. The current call does not clearly acknowledge the change from the earlier “nearly 10%” segment margin benefit to a current 6–7% estimate versus imports under stable conditions.

e. Evolution of Key Themes

Demand: Stable to modestly improving. Revenue growth has persisted, but dry-cell category volumes remain sluggish and rural demand faces monsoon uncertainty.
Margins/input costs: Deteriorating near term. Pricing actions continue, but costs have risen faster; recovery is now expected mainly by Q4.
Alkaline/premiumization: Improving. Share and volumes are growing, and local manufacturing has begun; the margin impact still needs to scale.
Jammu/manufacturing integration: Improving operationally; economics not yet proven. Production and billing have started, but Q2 sales were still largely imported.
Debt/financial flexibility: Improving. Noida proceeds reduced debt and management says no major capex is planned.
Lighting: Mixed. Emergency lighting and consumer products are growing, but professional lighting remains loss-making and the overall division is near breakeven.
Regulation: Mixed to deteriorating in uncertainty. BIS benefits remain unquantified; EPR and Jammu incentive matters are unresolved.

f. Additional Insights

Growth quality is shifting toward mix and new products: Management says half of H1 growth came from newer products, while the mature dry-cell market has sluggish volumes. The growth story may depend increasingly on premiumization and adjacencies rather than broad category expansion.
Jammu is strategically important but not yet a consolidated-margin catalyst: The plant’s output is only beginning to replace imports, and alkaline remains a relatively small share of the battery mix. Localization benefits could take time to become material.
Cash proceeds have accelerated the deleveraging narrative: The October collection makes the earlier two-year debt-free horizon look conservative, but that hinges on the absence of new major capex.
Management’s language has become more guarded even as results remain positive: The explicit “more difficult than H1” warning and the Q4 margin-recovery timetable are important counterweights to the repeated growth and premiumization narrative.

Eveready Warns H2 Tougher as Costs Pressure Margins